The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology.
Haverkamp
W
W
Breithardt
G
G
Camm
A J
AJ
Janse
M J
MJ
Rosen
M R
MR
Antzelevitch
C
C
Escande
D
D
Franz
M
M
Malik
M
M
Moss
A
A
Shah
R
R
D000200:Action Potentials / Q000187:drug effects*; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects; D000900:Anti-Bacterial Agents / Q000009:adverse effects; D014150:Antipsychotic Agents / Q000009:adverse effects; D002309:Cardiology; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D004335:Drug and Narcotic Control; D005060:Europe; D006801:Humans; D015221:Potassium Channels / Q000187:drug effects*; D011358:Product Surveillance, Postmarketing; D012106:Research; D012955:Societies, Medical; D016171:Torsades de Pointes / Q000139:chemically induced*; D014665:Vasodilator Agents / Q000009:adverse effects
D000889:Anti-Arrhythmia Agents; D000900:Anti-Bacterial Agents; D014150:Antipsychotic Agents; D015221:Potassium Channels; D014665:Vasodilator Agents